That is really impressive, we need that Phase III Data now!
Baranski was enrolled into the study according to the clinical trial protocol (which is randomized, meaning there is a 50/50 chance he was dosed with either lenzilumab or placebo) shortly after being transferred to St. Barnabas. It is important to note that all subjects participating in this study are able to receive other COVID-19 therapies that are considered standard of care. While it is not clear which treatment group Marc was assigned to, within 24 hours after receiving the study drug, his symptoms dramatically improved and within about a week, he was discharged from the hospital and has since made a full recovery.